|
|
|
|
|
27.02.26 - 18:54
|
Exercise Price Determined for the Exercise of Warrants Series TO 14 in Alligator Bioscience AB (Accesswire)
|
|
|
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH A......
|
|
|
27.02.26 - 18:24
|
Qlife announces that two investors have entered agreements to subscribe for shares if the rights issue is subscribed below approx. 51.0 percent, taking over commitments from a group of guarantors (Cision)
|
|
|
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE
Qlife Holding AB (publ) (“Qlife” or the “Company”) today announces that Jinderman & Partners AB and JJV Investment Group AB (the “Investors”) have entered into agreements to subscribe for shares if the Company's rights issue,...
|
|
|
27.02.26 - 15:30
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund, Sweden — 27 February 2026 — During February 2026, 54,550 employee stock options in Camurus' employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares.
As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 54,550.
Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,880,184 corresponding to 59,880,184 votes. As of 27 February 2026, the total number of shares in Camurus amounts to 59,934,734 corresponding to...
|
|
|
27.02.26 - 11:48
|
Change in number of shares and votes in Episurf Medical (Cision)
|
|
|
As a result of, in accordance with previously announced information, the exercise of 450,494,390 warrants of series TO14 B for subscription of the same number of new Class B shares, as well as the directed issue of 700,238,622 Class B shares, the number of shares and votes in Episurf Medical AB (publ) ("Episurf") has changed.
Through the above-mentioned changes, the total number of shares in Episurf amounts to 2,810,494,390, of which 473,357 are Class A shares and 2,810,021,033 are Class B shares, and the total number of votes in Episurf amounts to 2,811,441,104.
For further...
|
|
|
|
|
|
|
27.02.26 - 08:06
|
Peptonic Medical AB (publ) - Publishes Year-end report for 2025 (Cision)
|
|
|
Peptonic Medical AB (publ) ("Peptonic" or the "Company") publishes today, February 27, 2026, its year-end report for 2025.
Key figures for the Group - Fourth quarter (October – December)
· Sales of goods amounted to KSEK 3,539 (4,445).
· Gross profit amounted to KSEK 2,165 (2,563), corresponding to a gross margin of 61 (58) percent.
· Operating profit amounted to KSEK 998 (-26,749).
· Earnings per share amounted to SEK 0.0000001 (-0.005).
Key figures for the Group - Twelve months (January – December)
· Sales of goods amounted to KSEK 14,788 (26,891).
· Gross...
|
|
|
27.02.26 - 07:48
|
Cereno Scientific Publishes Year-end Report for 2025 (January 1 – December 31, 2025) (Cision)
|
|
|
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the Board of Directors and Chief Executive Officer of Cereno Scientific AB here presents the Year-end Report for 2025 (January 1 – December 31, 2025).
Financial overview
Cereno Scientific Group
Full year 2025
· Net Sales were SEK 0 (0)
· Result after financial items was SEK -117 754 773 (-99 525 680)
· Earnings per share was SEK -0.38 (-0.35) before dilution and SEK -0.33 (-0.32)...
|
|
|
|
|
|
|
26.02.26 - 12:01
|
BioGaia AB extends long-standing distribution partnership with Ewopharma (Cision)
|
|
|
BioGaia AB (NASDAQ: BIOG) has signed a renewed distribution agreement with Ewopharma. The extended agreement reinforces the companies' successful collaboration to date and reflects a shared ambition to further accelerate growth across the European region.
Ewopharma is a pharmaceutical marketing organization and commercialization partner active in Central Eastern Europe and Switzerland, with expertise spanning prescription medicines, OTC products, and Consumer Health.
Under the new agreement, Ewopharma will distribute a broad range of BioGaia's product portfolio in more than 15...
|
|
|
26.02.26 - 11:06
|
Bulletin from Extraordinary General Meeting 2026 of Qlife Holding AB (Cision)
|
|
|
Qlife Holding AB (the “Company” or “Qlife”) held an Extraordinary General Meeting on 26 February 2026, at which the following resolutions were adopted.
Resolution on amendment of the Articles of Association
The Extraordinary General Meeting resolved, in accordance with the Board of Directors' proposal, to amend the Articles of Association's limits for share capital and number of shares as follows.
Current Proposed amended wording
wording
§ 4 Share § 4 Share capitalThe share capital shall amount to a minimum of
capitalThe SEK 2,500,000 and a maximum of SEK 10,000,000....
|
|
|
26.02.26 - 10:43
|
Redsense Medical announces first Clamp System sale to UK clinic (Cision)
|
|
|
Halmstad, Sweden, February 26, 2026 – Redsense Medical AB (publ) (“Redsense'' or “the Company”) announces that the Company's UK distributor has received its first order for the Redsense Clamp System for delivery to an end customer in the UK.
The order covers two Clamp Systems purchased together with Redsense Alarm units for immediate implementation at a UK clinic. The distributor aims to build on this initial implementation through ongoing discussions regarding broader adoption, with Redsense supporting the process.
“This initial order is an important milestone and the first Clamp...
|
|
|
|
|
|
|
|
|
26.02.26 - 08:18
|
Tomas Puusepp appointed Chair of the Board at Permobil (Cision)
|
|
|
Tomas Puusepp, professional board member and former CEO of Elekta, has been appointed new Chair of the Board at Permobil. Puusepp, who has served on Permobil's Board for almost 10 years, will assume the role in June, succeeding Martin Lundstedt, who has chaired the Board since 2013, when Investor acquired Permobil.
“I am very pleased to welcome Tomas Puusepp as Permobil's new Chair and look forward to continuing to work together in this new role. His experience and long-standing commitment to the company will be invaluable as Permobil continues its growth journey. I would also like to...
|
|
|
26.02.26 - 08:06
|
Publication of half-year report 2025/2026 (Cision)
|
|
|
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July 2025 – December 2025. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report.
Second quarter (2025-10-01 – 2025-12-31)
· The Group's net sales amounted to SEK 10,932,119 (0).
· The Group's profit after financial items amounted to SEK 1,298,597 (-2,562,520).
· Result per share amounted to SEK 0.07 (-0.16).*
Six months (2025-07-01 – 2025-12-31)
· The Group's net sales amounted to SEK...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
